

# R H I N O M E D

## ASX ANNOUNCEMENT

*Not for release to U.S. wire services or distribution in the United States*

## Successful Completion of Institutional Entitlement Offer

**8 April 2022: Melbourne, Australia.**

Rhinomed Limited (ASX: RNO) (**Rhinomed**) is pleased to announce that it has successfully completed the institutional component of the partially underwritten accelerated non-renounceable entitlement offer (**Institutional Entitlement Offer**) originally announced on 7 April 2022, raising approximately \$3.37 million.

The retail component of the entitlement offer (**Retail Entitlement Offer**) will open on 13 April 2022. A maximum of approximately \$1.63 million may be raised under the Retail Entitlement Offer. Any amount to be raised under the Retail Entitlement Offer will be used for ongoing working capital.

### **Institutional Entitlement Offer**

The Institutional Entitlement Offer was strongly supported by existing institutional shareholders. Approximately \$3.37 million (approximately 17,736,117 million shares) was raised under the Institutional Entitlement Offer.

Shares issued under the Institutional Entitlement Offer will be issued at the same price as the Retail Entitlement Offer (\$0.19 per share) and are expected to be allotted on 19 April 2022.

### **Retail Entitlement Offer**

Eligible shareholders may participate in the Retail Entitlement Offer at the same price (\$0.19 per share) and offer ratio (1 new share for every 9.87 shares held) as the Institutional Entitlement Offer. Eligible shareholders' entitlements will be determined according to their ownership of shares on the record date for the Retail Entitlement Offer (7.00pm AEST on 11 April 2022).

Further details in relation to the Retail Entitlement Offer will be provided in the retail offer booklet, to be despatched to eligible shareholders on 13 April 2022. The offer closes at 5.00pm AEST on 29 April 2022.

Retail shareholders with questions about the Retail Entitlement Offer should call the Rhinomed Offer Information Line on 1 300 288 664 or +61 2 9698 5414 between 8.30am and 5.00pm AEST, Monday to Friday during the retail offer period (13 April 2022 to 29 April 2022).

Rhinomed shares are expected to resume trading on ASX from market open on Monday, 11 April 2022.

# R H I N O M E D

This report has been authorised for release to the market by the Board.

All dollar amounts are in Australian dollars unless otherwise indicated.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 <a href="mailto:mjohnson@rhinomed.global">mjohnson@rhinomed.global</a> Follow us on <b>Twitter</b> @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 <a href="mailto:rudim@monsoon.com.au">rudim@monsoon.com.au</a>

#### **About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)**

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.

#### **Not an offer in the United States**

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.